Surrozen (SRZN) Change in Receivables (2024 - 2026)

Surrozen (SRZN) posted quarterly Change in Receivables of $5.0 million for Q1 2026, up 345.22% quarter-over-quarter from -$2.0 million in Q4 2025.

Surrozen (SRZN) Change in Receivables (2024 - 2026) Analysis & Trends

Surrozen's Change in Receivables history runs 3 years deep, the most recent figure standing at $5.0 million for Q1 2026.

In Q1 2026, Change in Receivables changed N/A year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $3.0 million (changed N/A YoY), while the FY2025 annual figure was -$2.0 million, changed N/A from the prior year.
Change in Receivables for Q1 2026 stood at $5.0 million, up from -$2.0 million in the prior quarter.
The five-year high for Change in Receivables was $10.0 million in Q3 2024, with the low at -$10.0 million in Q4 2024.
The 3-year median for Change in Receivables is $0.0 (2025), against an average of $493500.0.
Peak annual rise in Change in Receivables reached 79.61% in 2025, while the deepest fall reached 97.5% in 2025.
Surrozen's Change in Receivables stood at -$10.0 million in 2024, then surged by 79.61% to -$2.0 million in 2025, then soared by 345.22% to $5.0 million in 2026.
Business Quant data shows SRZN's Change in Receivables at $5.0 million in Q1 2026, -$2.0 million in Q4 2025, and $250000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	117.58 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-483,662.49
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	31.60 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	37.16 Mn
10	Surrozen	281.63 Mn	281.63 Mn	-	-

Download Data